CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with BarostimNew real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsMINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024.
Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the FirmNEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arhaus, Inc (
NASDAQ: ARHS), Cardlytics, Inc. (
NASDAQ: CDLX), and CVRx, Inc. (
NASDAQ: CVRX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx, Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the FirmNEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CVRx, Inc. (“CVRx” or the “Company”) (NASDADQ: CVRX) on behalf of CVRx stockholders. Our investigation concerns whether CVRx has violated the federal securities laws and/or engaged in other unlawful business practices.
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (
NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CVRX.
CVRX Investors Have Opportunity to Join CVRx, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or “the Company”) (
NASDAQ: CVRX) for violations of the securities laws.
Bronstein, Gewirtz & Grossman, LLC Notifies CVRx, Inc. (CVRX) Investors of Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors of CVRx, Inc. (“CVRx” or “the Company”) (
NASDAQ: CVRX). CVRx investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/cvrx.
CVRx Appoints Industry Veteran Kevin Hykes to Board of DirectorsMINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (
NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022.
CVRx Launches new Barostim NEO2™ Implantable Pulse GeneratorThe new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians
